WA-AGC-BIOLOGICS
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a capacity update with the addition of three new Grade B cell therapy suites to its Longmont, CO facility.
The new addition at AGC Biologics Longmont provides 2 new Process Suites and 1 new Flex suite, bringing expanded capabilities to this Colorado site. With more than 30,000 square feet of added space, the new segregated, multiproduct suites feature state-of-art modular clean room design, flexible capacity configuration, and the latest cell therapy equipment for open and closed processes, offering autologous and allogeneic cell therapy manufacturing.
The three new cell therapy suites bring additional capacity for AGC Biologics’ North American hub for cell and gene therapy services. Now, AGC Biologics Longmont can offer end-to-end cell therapy development and manufacturing services in one location. The new labs extend the capabilities at the site and complement the site’s robust viral vector development and manufacturing services, offering unique benefits to developers looking for one centralized location that can offer a full set of services for bringing their products to market. Other key features of this site include support for early-stage process development services, commercial manufacturing, quality control and analytics, fill-finish capabilities, and an onsite warehouse. With ample space at the Longmont campus, AGC Biologics can add nine additional cell therapy suites to meet additional market demand.
“The new cell therapy suites are a tremendous achievement for this site. We have integrated the latest technology to complete our unique cell therapy services and have created ideal environments for developing these life-changing treatments,” said Whitney Sandberg, General Manager, AGC Biologics Colorado. “This is the final piece for this campus that accompanies our comprehensive viral vector capabilities and gives developers a true end-to-end manufacturing site in North America to support their product’s every need, at any stage.”
AGC Biologics acquired the Longmont campus in August of 2021. The scientists in Longmont have an established track record of 20+ years of experience working with complex cell therapy and viral vector products and substances.
AGC Biologics offers end-to-end global viral vector and cell therapy development, manufacturing, and quality/regulatory services. AGC Biologics’ team has supported four commercial viral vector products, three commercial cell therapies and more than 30 cell and gene therapy clinical trials across Europe and the United States. The CDMO operates two C> facilities, one in Milan and one in Longmont. Supported by scientists with 30 years of knowledge and experience, the company uses the latest technology and platforms to help navigate the growing advanced therapies market.
Earlier this year, AGC Biologics announced formal proprietary platforms for lentiviral vector production and adeno-associated viral vector production to complement its global cell and gene services, ProntoLVV™ and BravoAAV™.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230823713211/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International’s WorldFirst Accelerates SEA Growth with Malaysia MSB Licence7.8.2025 09:04:00 CEST | Press release
Ant International receives Bank Negara Malaysia Class A Money Services Business licence for WorldFirst to operate cross-border payment services.This new licence strengthens WorldFirst’s product and service offerings for businesses expanding into and out of Malaysia.The licence adds to WorldFirst’s portfolio of over 60 licences across Asia, Europe, North America and Oceania. Ant International has obtained approval from Bank Negara Malaysia to carry out business under a Class A Money Services Business licence. The licence will empower Ant International’s WorldFirst—an all-in-one digital cross-border payment and treasury account service for global businesses—to operate in Malaysia, adding to its 60+ global licences worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806541491/en/ WorldFirst's All-in-One Business Account for Global Payments The licence will enable WorldFirst to expand its product offerings and roll out
Objectway Accelerates Its Growth Path Through an Investment From Cinven in Partnership With Its Founder Luigi Marciano and the Existing Management Team7.8.2025 09:00:00 CEST | Press release
The majority investment marks the start of a new phase of growth for Objectway, leveraging its resilient and scalable business model, its end-to-end solution-as-a-service platform, and long-term partnerships with a blue-chip customer base. Luigi Marciano, founder of Objectway, a leading provider of software and services to financial institutions across Europe, North America and the Middle East, along with Objectway’s management team and international private equity firm, Cinven, today announced an agreement under which Cinven will make a majority investment in Objectway. Luigi Marciano will remain a significant shareholder alongside Cinven, and continue in his role as CEO and Chair. He and his existing management team will continue to manage the business, and Cinven’s backing will provide strategic and financial support, including continued investment in technology innovation, as well as support for future organic growth and targeted M&A opportunities. Together, Luigi Marciano, his tea
Art Collective teamLab to Open New Museum, teamLab Biovortex Kyoto on October 7, 20257.8.2025 08:00:00 CEST | Press release
Unveiling 7 artworks, including pieces never before exhibited in Japan. Tickets on Sale now teamLab Biovortex Kyoto, art collective teamLab’s permanent art museum, is set to open in Minami-ku, Kyoto, as part of the Kyoto Station Southeast Area Project on October 7, 2025. This will be teamLab's largest museum in Japan, spanning over 10,000 square meters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806347101/en/ Even if individual elements are separated in space and time, when a structural order appears among them, the elements transcend space and time and form a single entity. Despite significant changes in shape or size on the surface, or even if all of the elements are replaced, the single existence will be maintained. This spatiotemporal existence is part of the whole, it appears from the whole, and is returned to it. It is a living universe - a biocosmos. (teamLab, Morphing Continuum © teamLab) In preparation for th
Allianz Announces Excellent Performance and Is Fully on Track for Full-year Ambitions7.8.2025 07:13:00 CEST | Press release
2Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806235547/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Allianz achieves strong growth and record operating profitTotal business volume rises 8.01 percent to 44.5 billion euros, supported by good growth across all segments Operating profit increases 12.2 percent and reaches a record level of 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 17.3 percent and reaches 3.0 billion euros. Adjusted for the 0.3 billion euros disposal gain on the UniCredit Joint Venture, shareholders’ core net income increases 7.1 percent 6M 2025 Excellent performance across our businesses and record operating profitTotal business volume grows 10.1 1 percent and reaches 98.5 billion euros, with contributions from all segments Operating profit increases 9.3 percent to 8.6 billion euros, our highest half-
New pulp mill boosts Suzano's sales and revenue in the second quarter of 20257.8.2025 04:17:00 CEST | Press release
Suzano, the world’s largest pulp producer, announces its results for the second quarter of 2025 (2Q25), reporting sales of 3.7 million tonnes of pulp and paper. Sales increased 28% over the same period in 2024 (2Q24), mainly reflecting the strong operational contribution of the new Ribas do Rio Pardo pulp mill, whose production started in July 2024. Net revenue in the quarter totaled R$13.3 billion, a 16% increase compared to 2Q24. The expansion of pulp production capacity in Brazil, combined with the positive contribution to paper sales from the mills recently acquired in the United States and favorable FX rates, mitigated the impact on net revenue of lower pulp prices in the global market compared to 2Q24. As a result, Suzano's adjusted EBITDA reached R$6.1 billion and operating cash generation totaled R$4.1 billion. Net profit totaled R$5.0 billion positively impacted by the accounting impact of US dollar denominated debt and hedging operations translating into Brazilian Real. Beto
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom